Omeros (NASDAQ:OMER) CAO David Borges Sells 5,000 Shares of Stock

Omeros Corporation (NASDAQ:OMER) CAO David Borges sold 5,000 shares of the business’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $16.95, for a total value of $84,750.00. Following the sale, the chief accounting officer owned 5,000 shares in the company, valued at approximately $84,750. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Omeros Stock Up 1.0%

Shares of NASDAQ:OMER traded up $0.17 during trading on Monday, hitting $17.36. The stock had a trading volume of 2,466,385 shares, compared to its average volume of 2,290,120. Omeros Corporation has a 12-month low of $3.94 and a 12-month high of $18.14. The stock has a 50-day simple moving average of $11.04 and a two-hundred day simple moving average of $11.58. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of 13.56 and a beta of 2.54.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. As a group, sell-side analysts forecast that Omeros Corporation will post -0.37 earnings per share for the current year.

Institutional Investors Weigh In On Omeros

A number of institutional investors have recently added to or reduced their stakes in OMER. International Assets Investment Management LLC grew its stake in Omeros by 16.0% during the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 800 shares in the last quarter. Farther Finance Advisors LLC lifted its position in Omeros by 16.5% during the fourth quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 1,004 shares in the last quarter. State of Wyoming purchased a new position in Omeros during the fourth quarter worth approximately $25,000. AQR Capital Management LLC raised its holdings in shares of Omeros by 7.2% during the 4th quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company’s stock worth $392,000 after acquiring an additional 1,532 shares during the period. Finally, ProShare Advisors LLC boosted its position in shares of Omeros by 12.1% during the 4th quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 1,637 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on OMER shares. D. Boral Capital reiterated a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating on shares of Omeros in a research note on Monday, July 27th. Wall Street Zen raised shares of Omeros from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings raised shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Finally, Zacks Research lowered shares of Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $38.00.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.